1. Home
  2. TR vs MLYS Comparison

TR vs MLYS Comparison

Compare TR & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tootsie Roll Industries Inc.

TR

Tootsie Roll Industries Inc.

HOLD

Current Price

$43.01

Market Cap

3.1B

ML Signal

HOLD

Logo Mineralys Therapeutics Inc.

MLYS

Mineralys Therapeutics Inc.

HOLD

Current Price

$26.40

Market Cap

1.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TR
MLYS
Founded
1896
2019
Country
United States
United States
Employees
2100
N/A
Industry
Specialty Foods
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.1B
1.9B
IPO Year
N/A
2023

Fundamental Metrics

Financial Performance
Metric
TR
MLYS
Price
$43.01
$26.40
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$48.67
AVG Volume (30 Days)
117.9K
1.2M
Earning Date
04-23-2026
03-12-2026
Dividend Yield
0.84%
N/A
EPS Growth
N/A
37.43
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$32.36
N/A
Revenue Growth
N/A
N/A
52 Week Low
$29.13
$10.44
52 Week High
$44.27
$47.65

Technical Indicators

Market Signals
Indicator
TR
MLYS
Relative Strength Index (RSI) 61.31 51.05
Support Level $40.07 $22.42
Resistance Level $43.37 $31.09
Average True Range (ATR) 1.26 1.62
MACD 0.06 0.38
Stochastic Oscillator 75.14 59.63

Price Performance

Historical Comparison
TR
MLYS

About TR Tootsie Roll Industries Inc.

Tootsie Roll Industries Inc manufactures and sells confectionery products. Notable varieties include Tootsie Roll and Tootsie Pops, Charms, Blow-Pops, Dots, Junior Mints, Sugar Daddy and Sugar Babies, Andes, Dubble Bubble, Razzles among others. The company sells its products to wholesale distributors and directly to retail stores. Geographically, it generates a majority of its revenue from the United States and rest from Canada, Mexico and other regions.

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.

Share on Social Networks: